Continuous low doses of far ultraviolet C (far-UVC) light can kill airborne flu viruses without harming human tissues, according to a new study at the Center for Radiological Research at Columbia University Irving Medical Center (CUIMC). The findings suggest that use of overhead far-UVC light in hospitals, doctors’ offices, schools, airports, airplanes, and other public spaces could provide a powerful check on seasonal influenza epidemics, as well as influenza pandemics.
Scientists have known for decades that broad-spectrum UVC light, which has a wavelength of between 200 to 400 nanometers, or nm), is highly effective at killing bacteria and viruses by destroying the molecular bonds that hold their DNA together. This conventional UV light is routinely used to decontaminate surgical equipment.
“Unfortunately, conventional germicidal UV light is also a human health hazard and can lead to skin cancer and cataracts, which prevents its use in public spaces,” said study leader David J. Brenner, PhD, the Higgins Professor of Radiation Biophysics at the Vagelos College of Physicians and Surgeons and director of the Center for Radiological Research at Columbia.
Several years ago, Brenner and his colleagues hypothesized that a narrow spectrum of ultraviolet light called far-UVC could kill microbes without damaging healthy tissue. “Far-UVC light has a very limited range and cannot penetrate through the outer dead-cell layer of human skin or the tear layer in the eye, so it’s not a human health hazard. But because viruses and bacteria are much smaller than human cells, far-UVC light can reach their DNA and kill them,” said Brenner, who is also a professor of environmental health sciences at Columbia’s Mailman School of Public Health.
Airborne-mediated microbial diseases such as influenza and tuberculosis represent major public health challenges. A direct approach to prevent airborne transmission is inactivation of airborne pathogens, and the airborne antimicrobial potential of UVC ultraviolet light has long been established; however, its widespread use in public settings is limited because conventional UVC light sources are both carcinogenic and cataractogenic. By contrast, we have previously shown that far-UVC light (207–222 nm) efficiently inactivates bacteria without harm to exposed mammalian skin. This is because, due to its strong absorbance in biological materials, far-UVC light cannot penetrate even the outer (non living) layers of human skin or eye; however, because bacteria and viruses are of micrometer or smaller dimensions, far-UVC can penetrate and inactivate them. We show for the first time that far-UVC efficiently inactivates airborne aerosolized viruses, with a very low dose of 2 mJ/cm2 of 222-nm light inactivating over 95% of aerosolized H1N1 influenza virus. Continuous very low dose-rate far-UVC light in indoor public locations is a promising, safe and inexpensive tool to reduce the spread of airborne-mediated microbial diseases.
A key advantage of the UVC based approach, which is in clear contrast to vaccination approaches, is that UVC light is likely to be effective against all airborne microbes. For example, while there will almost certainly be variations in UVC inactivation efficiency as different influenza strains appear, they are unlikely to be large. Likewise, as multi-drug-resistant variants of bacteria emerge, their UVC inactivation efficiencies are also unlikely to change greatly.
In conclusion, we have shown for the first time that very low doses of far-UVC light efficiently inactivate airborne viruses carried by aerosols. For example, a very low dose of 2 mJ/cm2 of 222-nm light inactivates >95% of airborne H1N1 virus. Our results indicate that far-UVC light is a powerful and inexpensive approach for prevention and reduction of airborne viral infections without the human health hazards inherent with conventional germicidal UVC lamps. If these results are confirmed in other scenarios, it follows that the use of overhead very low level far-UVC light in public locations may represent a safe and efficient methodology for limiting the transmission and spread of airborne-mediated microbial diseases. Public locations such as hospitals, doctors’ offices, schools, airports and airplanes might be considered here. This approach may help limit seasonal influenza epidemics, transmission of tuberculosis, as well as major pandemics.
In their earlier studies, Brenner’s team demonstrated that far-UVC light was effective at killing MRSA (methicillin-resistant S. aureus) bacteria, a common cause of surgical wound infections but not harm human or mouse skin.
Influenza virus spreads from person to person mainly through fine liquid droplets, or aerosols, that become airborne when people with flu cough, sneeze, or talk. The new study was designed to test if far-UVC light could efficiently kill aerosolized influenza virus in the air, in a setting similar to a public space.
In the study, aerosolized H1N1 virus—a common strain of flu virus—was released into a test chamber and exposed to very low doses of 222 nm far-UVC light. A control group of aerosolized virus was not exposed to the UVC light. The far-UVC light efficiently inactivated the flu viruses, with about the same efficiency as conventional germicidal UV light.
“If our results are confirmed in other settings, it follows that the use of overhead low-level far-UVC light in public locations would be a safe and efficient method for limiting the transmission and spread of airborne-mediated microbial diseases, such as influenza and tuberculosis,” Brenner said.
At a price of less than $1,000 per lamp—a cost that would surely decrease if the lamps were mass produced—far-UVC lights are relatively inexpensive. “And unlike flu vaccines, far-UVC is likely to be effective against all airborne microbes, even newly emerging strains,” Brenner added.
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.